Header Navigation

Type 2 diabetes mellitus (T2D) leads to an increased infarct size in postmenopausal women. The G protein-coupled estrogen receptor (GPER) may be decisive here. This oestrogen receptor mediating rapid non-genomic effects. Its expression is reduced both during menopause and in T2D. This is of great relevance as GPER is protective in myocardial infarction. We hypothesize that estrogen as a GPER activator in the infarct is therefore a potential therapeutic target. This will be investigated in murine analyses in the menopausal model with T2D and infarction.

Parkinson's syndrome affects millions worldwide, causing movement disorders such as slowness, tremors, and gait instability. Over 70% of patients also experience sensory disturbances, including pain, abnormal sensations, loss of smell, visual impairments, and hallucinations. These significantly reduce quality of life, yet effective treatments are still lacking. This research project aims to precisely map the underlying brain networks.

Viral infections can lead to a misdirected autoimmune response, in which the antibodies attack the own body (called anti-PF4 antibodies). They activate blood platelets and trigger life-threatening blood clots, e.g. in the brain. People of all ages can be affected, from young children to the elderly. Patients need to be diagnosed as quickly as possible to rapidly start treatment. This project aims to identify the mechanisms of disease development at a molecular level.

Parkinson's is characterized by both motor (e.g. shaking) and non-motor symptoms such as anxiety and sleep problems. The stigma of Parkinson’s plays a major role for patients and can be summarised simply as reactions of others (e.g. staring) as well as the

Sarcomas are malignant, locally aggressive tumors that metastasize at an early stage. In this project, the scientists are investigating methods that can show whether and how a sarcoma responds to radiation before surgery. They examine patients with sarcomas before, during and after radiotherapy using a special MRI procedure and determine tumor-specific DNA fragments in the blood as a so-called "liquid biopsy" to determine tumor activity during therapy and to detect recurrences or metastases at an early stage during follow-up.